Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia (CLL) is a low-grade lymphoproliferative malignancy in which there is a proliferation of small mature lymphocytes (almost always B cells) in the blood, bone marrow, spleen, and lymph nodes. CLL is the most common type of leukemia in the Western world.
CLL occurs mainly in the elderly; 75% of cases are diagnosed in patients > 60 years. CLL is twice as common in men. Although the cause is unknown, some cases appear to have a hereditary component. The disease is rare in Japan and China.
There is usually gradual onset of fatigue, malaise, and lymphadenopathy. Infections are not infrequent and bleeding problems occur in the last stages of the disease.
On examination, there is usually lymphadenopathy and splenomegaly. Hepatomegaly is usually a late feature.
CLL is confirmed by examining the peripheral smear and bone marrow; the hallmark is sustained, absolute peripheral lymphocytosis (> 5000/μL) and increased lymphocytes (> 30%) in the bone marrow.
In about 98% of cases, CD5+ B cells undergo malignant transformation, with lymphocytes initially accumulating in the bone marrow and then spreading to lymph nodes and other lymphoid tissues, eventually inducing splenomegaly and hepatomegaly.
As CLL progresses, abnormal hematopoiesis results in anemia, neutropenia, thrombocytopenia, and decreased immunoglobulin production.
Many patients develop hypogammaglobulinemia and impaired antibody response, perhaps related to increased T-suppressor cell activity.
Patients have increased susceptibility to autoimmune disease characterized by immune hemolytic anemia (usually Coombs test–positive) or immune thrombocytopenia and a modest increase in the risk of developing other cancers.
In 2 to 3% of cases, the clonal expansion is T cell in type, and even this group has a subtype (eg, large granular lymphocytes with cytopenias).
In addition, other chronic leukemic patterns have been categorized under CLL:
- Prolymphocytic leukemia (PLL).
- Leukemic phase of cutaneous T-cell lymphoma (Sézary syndrome).
- Hairy cell leukemia.
- Lymphoma progressing to leukemia (ie, leukemic changes that occur in advanced stages of malignant lymphoma).
Differentiation of these subtypes from typical CLL is usually made by using light microscopy and phenotyping.
There is usually a mild normocytic anemia. This becomes more marked as the disease progresses or if there is associated autoimmune hemolytic anemia (5-10%).
The granulocyte count and platelet count only to fall late in the disease.
Most cases of CLL are B-cell neoplasms, however, rare cases of CLL are T-cell neoplasms.
In patients with CLL, the full blood count (FBC) with differential shows absolute lymphocytosis, with more than 5000 B-lymphocytes/µL. Lymphocytosis must persist for longer than 3 months. Clonality must be confirmed by flow cytometry. The presence of a cytopenia caused by clonal bone marrow involvement establishes the diagnosis of CLL regardless of the peripheral B-lymphocyte count.
Patients with fewer than 5000 B-lymphocytes/µL with lymphadenopathy and without cytopenias more likely have small lymphocytic lymphoma (SLL), although this diagnosis should be confirmed by lymph node biopsy.
Patients with a clonal B-cell population less than 5000/µL without lymphadenopathy or organomegaly, cytopenia, or other disease-related symptoms have monoclonal B-lymphocytosis (MBL). MBL will progress to CLL at a rate of 1-2% per year.
Microscopic examination of the peripheral blood smear is indicated to confirm lymphocytosis. It usually shows small lymphocytes predominating and the presence of smudge (smear) cells, which are artifacts from lymphocytes damaged during the slide preparation.
Large atypical cells, cleaved cells, and prolymphocytes are also often seen on the peripheral smear and may account for up to 55% of peripheral lymphocytes. If this percentage is exceeded, prolymphocytic leukemia (B-cell PLL) is a more likely diagnosis.
Peripheral blood flow cytometry is the most valuable test to confirm a diagnosis of CLL. It confirms the presence of circulating clonal B-lymphocytes expressing CD5 (normally expressed on T cells), CD19, CD20, CD23, and an absence of CD10 and FMC-7 staining. The cells express light-chain restricted monoclonal Ig, usually IgM ± IgD.
Immunophenotyping is essential for the diagnosis of CLL. The scoring proposed in the modified Matutes score has been the basis of diagnosis for the past 15 years and is defined by strong expression of CD5 and CD23, low or absent expression of CD79b, sIgM, and FMC7.
Bone marrow aspiration and biopsy with flow cytometry are not required in all cases of CLL, but it may be necessary in selected cases to establish the diagnosis and to assess other complicating features such as anemia and thrombocytopenia. For example, bone marrow examination may be necessary to distinguish between thrombocytopenia of peripheral destruction (in the spleen) and that due to marrow infiltration.
Consider a lymph node biopsy if lymph nodes begin to enlarge rapidly in a patient with known CLL, to assess the possibility of transformation to a high-grade lymphoma. When such transformation is accompanied by fever, weight loss, and pain, it is termed Richter syndrome.
The bone marrow is infiltrated by small lymphocytes.
Biopsy of affected lymph nodes shows a diffuse infiltration with small lymphocytes.
hypogammaglobulinemia occurs in one-third; ‘M’ bands (usually IgM) are found in approximately 5%.
Consider obtaining serum quantitative immunoglobulin levels in patients developing repeated infections, because monthly intravenous immunoglobulin administration in patients with low levels of immunoglobulin G (IgG) (<0.5 gm) may be beneficial in reducing the frequency of infectious episodes.
A positive direct Coombs test (DCT) occurs in 25% of cases (usually without hemolysis) at some stage during the disease.
Chromosomal evaluation using FISH can identify certain chromosomal abnormalities of CLL with prognostic significance.
Patients with a deletion in the short arm of chromosome 17 [del(17p)/p53 gene] tend to have a worse prognosis, as well as resistance to therapy with alkylating agents and purine analogues.
Patients with deletions in the long arm of chromosome 11 [del(11q)/ATM gene] also have a worse prognosis and bulky lymphadenopathy at presentation.
The poor prognosis seen with del(17p) and del (11q) are independent of the patient’s stage at presentation. Patients with these abnormalities may benefit from treatment with the monoclonal antibody alemtuzumab.
IgVH status has shown potential as a prognostic marker for CLLas well. ZAP-70 and CD38 expression tend to correlate with unmutated IgVH and a poorer prognosis; however, these associations are not absolute.
None of the poor prognostic markers has been validated as an indication to initiate treatment in asymptomatic patients.
Two staging systems are in common use for CLL: the modified Rai staging in the United States and the Binet staging in Europe. Neither is completely satisfactory, and both have often been modified.
The differential diagnosis of CLL includes several other entities, such as hairy cell leukemia, which is moderately positive for surface membrane immunoglobulins of multiple heavy-chain classes and is typically negative for CD5 and CD21.
Prolymphocytic leukemia has a typical phenotype that is positive for CD19, CD20, and surface membrane immunoglobulin; one-half will be negative for CD5.
Large granular lymphocytic leukemia has a natural killer (NK) cell phenotype (CD2, CD16, and CD56) or a T-cell immunophenotype (CD2, CD3, and CD8).
The pattern of positivity for CD19, CD20, and the T-cell antigen CD5 is shared only by mantle cell lymphoma (MCL); these cells generally do not express CD23.
- Symptom amelioration.
- Supportive care.
- Specific therapy.
Patients with CLL do not need to be treated with chemotherapy until they become symptomatic or display evidence of rapid progression of disease, as characterized by the following:
- Weight loss of more than 10% over 6 months.
- Extreme fatigue.
- Fever related to leukemia for longer than 2 weeks.
- Night sweats for longer than 1 month.
- Progressive marrow failure (anemia or thrombocytopenia).
- Autoimmune anemia or thrombocytopenia not responding to steroids.
- Progressive or symptomatic splenomegaly.
- Massive or symptomatic lymphadenopathy.
- Progressive lymphocytosis, as defined by an increase of > 50% in 2 months or a doubling time of less than 6 months.
Supportive care includes:
- Transfusion of packed RBCs or erythropoietin injections for anemia.
- Platelet transfusions for bleeding associated with thrombocytopenia.
- Antimicrobials for bacterial, fungal, or viral infections.
Because neutropenia and hypogammaglobulinemia limit bacterial killing, antibiotic therapy should be bactericidal. Therapeutic infusions of γ-globulin should be considered in patients with hypogammaglobulinemia and repeated or refractory infections or for prophylaxis when ≥ 2 severe infections occur within 6 months.
Specific therapy includes:
- Monoclonal antibody therapy.
- Radiation therapy.
These modalities may alleviate symptoms and prolong survival. Overtreatment is more dangerous than undertreatment.
Alkylating drugs, especially chlorambucil, alone or with corticosteroids, have long been the usual therapy for B-cell CLL. However, fludarabine is more effective. Combination chemotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) more often induces complete remissions. It also lengthens remission duration and prolongs survival.
A phase III trial comparing bendamustine to chlorambucil in treatment-naive patients who were not deemed candidates for more aggressive regimens like FCR showed no improvement in overall survival but did show a complete response (21% vs 10%) and progression-free survival (21 months vs 9 months) favoring bendamustine without compromising the quality of life.
A bendamustine/rituximab combination has had some renewed interest. In a German phase II study of 72 pretreated patients, the overall response rate was 59%, and PFS was almost 15 months.
Patients with prolymphocytic leukemia and lymphoma leukemia usually require multidrug chemotherapy e.g. rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), and often respond only partially.
Interferon alfa, deoxycoformycin, and 2-chlorodeoxyadenosine (cladribine) are highly effective for hairy cell leukemia.
Autoimmune hemolytic anemia and thrombocytopenia are indications for corticosteroids.
Prednisone 1 mg/kg po once/day may occasionally result in striking, rapid improvement in patients with advanced CLL, although the response is often brief. The metabolic complications and increasing rate and severity of infections warrant caution in its prolonged use.
Prednisone used with fludarabine increases the risk of Pneumocystis jirovecii pneumonia formerly known as Pneumocystis carinii pneumonia (PCP) and Listeria infections and requires PCP prophylaxis with oral septrin or pentamidine inhalation.
Rituximab is the first monoclonal antibody used in the successful treatment of lymphoid cancers. In previously untreated patients, the response rate is 75%, with 20% of patients achieving complete remission.
Alemtuzumab (MabCampath) has a 33% response rate in previously treated patients refractory to fludarabine and a 75 to 80% response rate in previously untreated patients. More problems with immunosuppression occur with alemtuzumab than with rituximab.
Rituximab has been combined with fludarabine and with fludarabine and cyclophosphamide; these combinations have markedly improved the complete remission rate in both previously treated and untreated patients.
Alemtuzumab is now being combined with rituximab and with chemotherapy to treat minimal residual disease (MCR) and has effectively cleared bone marrow infiltration. Reactivation of cytomegalovirus and other opportunistic infections has occurred with alemtuzumab. Reactivation of hepatitis B infection may occur with rituximab.
Obinutuzumab (Gazyva) is a newer CD20-directed cytolytic monoclonal antibody that targets the same CLL cell surface protein as rituximab. The combination of obinutuzumab and chlorambucil was recently found to be superior to rituximab in prolonging progression-free survival and achieving a complete response to treatment. In combination with bendamustine, obinutuzumab can be used for the treatment of patients with follicular lymphoma (FL) who have had prior therapy with a rituximab-containing regimen.
Bruton tyrosine kinase inhibitors:
Bruton tyrosine kinase (BTK) is a nonreceptor tyrosine kinase that plays a central role in the signal transduction of the B-cell antigen receptor and other cell surface receptors, both in normal and malignant B lymphocytes. B-cell antigen receptor signaling is activated in secondary lymphatic organs and drives the proliferation of malignant B-cells, including CLL cells. During the last 10 years, BTK inhibitors (BTKi) are increasingly replacing chemotherapy-based regimens, especially in patients with CLL and mantle cell lymphoma (MCL). BTKi are particularly active in patients with CLL and MCL, but also received approval for Waldenström macroglobulinemia, small lymphocytic lymphoma, marginal zone lymphoma, and chronic graft-versus-host disease. Current clinical practice is continuous long-term administration of BTKi, which can be complicated by adverse effects or the development of drug resistance. Alternatives to long-term use of BTKi are being developed, such as combination therapies, permitting limited duration therapy. Second-generation BTKi are under development, which differ from ibrutinib, the first-in-class BTKi, in their specificity for BTK, and therefore may differentiate themselves from ibrutinib in terms of adverse effects or efficacy.
Ibrutinib (Imbruvica) is a novel, oral inhibitor of BTK. Ibrutinib appears to be highly active in CLL, particularly in the presence of 17p deletion or TP53 mutations, and has induced durable remissions in some patients with relapsed or refractory CLL. Its role as a single agent or as part of combination chemotherapy is evolving. Ibrutinib is also active in relapsed or refractory MCL and Waldenström’s macroglobulinemia. Ibrutinib monotherapy and idelalisib in combination with rituximab induce responses in the majority of patients in whom chemoimmunotherapy has failed, and these patients have improved outcomes.
Ibrutinib is indicated for CLL/SLL as a monotherapy or in combination with rituximab or obinutuzumab, or with bendamustine and rituximab (BR) combination at a dose of 420 mg PO daily until unacceptable toxicity or disease progression. Ibrutinib is also indicated in patients with mantle cell lymphoma (MCL) who have received at least 1 previous therapy at a dose of 560 mg PO daily until disease progression or unacceptable toxicity.
Acalabrutinib (Calquence) is a novel second-generation BTK inhibitor and has shown promising safety and efficacy profiles in patients with relapsed CLL and pretreated MCL. Recently, acalabrutinib was approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who received at least one prior therapy. However, clinical trials on a direct comparison between ibrutinib and acalabrutinib and on combination treatment options with other agents such as CD20 antibodies are warranted.
The way that both acalabrutinib and ibrutinib work is by irreversibly binding to and destroying the cancerous B lymphocytes. Acalabrutinib’s increased selectivity means that the risk of off-target cells, or noncancerous cells, is much lower than in ibrutinib, which thus results in a lower risk of adverse effects. Acalabrutinib is indicated for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL) at a dose of 100 mg PO q12hr until disease progression or unacceptable toxicity.
Idelalisib (Zydelig 150mg tablets) is indicated in combination with an anti-CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with CLL who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.
In 2015, the US Food and Drug Administration (FDA) granted breakthrough therapy designation to venetoclax (Venclexta) for subjects with CLL who have relapsed or have been refractory to previous treatment and have the 17p deletion genetic mutation. Venetoclax is a highly selective inhibitor of BCL2, which was shown to have substantial anti-tumor activity in patients with relapsed CLL, including those with poor prognostic features. Responses appeared to be more durable among those who had a complete response than among those with a partial response. Gradual dose escalation appeared to minimize the risk of tumor lysis syndrome, the major toxicity associated with venetoclax. Targeted treatment with venetoclax–obinutuzumab has been shown to be effective in previously untreated patients with CLL and coexisting conditions and resulted in a significantly higher percentage of patients with PFS than standard treatment with chlorambucil–obinutuzumab.
In Ireland, since December 2018, venetoclax has been reimbursed for the treatment of CLL; in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor; and in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor. Since 2020 it has been reimbursed in combination with rituximab for the treatment of adult patients with CLL who have received at least one prior therapy; and, as of March 2022, in combination with obinutuzumab for the treatment of adult patients with previously untreated CLL.
In general, monoclonal antibodies are well tolerated, although they may cause allergic reactions and significant immunosuppression. This favorable toxicity profile allows these agents to be combined with conventional chemotherapy, often with excellent clinical efficacy.
Local irradiation for palliation may be given to areas of lymphadenopathy or for liver and spleen involvement that does not respond to chemotherapy. Total body irradiation in small doses is occasionally successful in temporarily ameliorating symptoms.
CAR T-cell therapy:
In chimeric antigen receptor (CAR) T-cell therapy, a patient’s own genetically modified T-cells are engineered to express receptors that latch on to a specific cell surface protein, connecting them to cancer cells to be destroyed.
CAR T-cell therapy has already achieved remarkable remissions in some difficult-to-treat patients with B-cell malignancies. Although the clinical experience in CLL patients is limited, the proportion of remissions reached in this disease is clearly the lowest in the spectrum of B-cell tumors.
Currently, CAR T-cell therapy is US FDA approved as the standard of care for:
- Some forms of aggressive, relapsed, or refractory non-Hodgkin lymphoma including diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, high-grade B-cell lymphoma, transformed follicular lymphoma, and mantle cell lymphoma.
- Relapsed or refractory follicular lymphoma.
- Relapsed or refractory multiple myeloma.
- Relapsed or refractory acute lymphoblastic leukemia.
There are also many clinical trials of CAR T-cell therapy for other types of blood cancer and solid tumors.
CAR-T therapy is available in more than 15 EU countries, has been publicly available in England through the NHS since 2018, and has very recently made its way to Ireland.
In the United States the increasing number of Food and Drug Administration (FDA)-approved, innovative, and potentially effective commercial cancer therapies pose a significant financial burden on public and private payers. Chimeric antigen receptor (CAR) T cells are prototypical of this challenge. In 2017 and 2018, tisagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite) were approved by the FDA for use after showing groundbreaking results in relapsed/refractory B-cell malignancies. In 2020 and 2021, four further submissions to the FDA are expected for CAR T-cell therapies for indolent and aggressive B-cell malignancies and plasma cell myeloma. Yet, with marketed prices of over $350,000 per infusion for the two FDA-approved therapies and similar price tags expected for the coming products, serious concerns are raised over value and affordability.
The median survival of patients with B-cell CLL or its complications is about 7 to 10 yr. Patients in Rai stage 0 to II at diagnosis may survive for 5 to 20 yr without treatment. Patients in Rai stage III or IV are more likely to die within 3 to 4 yr of diagnosis. Progression to bone marrow failure is usually associated with short survival. Patients with CLL are more likely to develop secondary cancer, especially skin cancer.
Muhammad A Mir, MD, FACP Chronic Lymphocytic Leukemia: Practice Essentials, Background, Pathophysiology http://emedicine.medscape.com/article/199313
Badoux XC, Keating MJ, Wang X, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011 Jan 18.
Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008 Jun 15. 111(12):5446-56.
Abbott BL. Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. Oncologist. 2006 Jan. 11(1):21-30.
Zwiebel JA, Cheson BD. Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol. 1998 Feb. 25(1):42-59.
Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007 Dec 10. 25(35):5616-23.
Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011 Sep 10. 29(26):3559-66.
Richard R. Furman, M.D., Jeff P. Sharman, M.D., et al. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 2014; 370:997-1007 http://www.nejm.org/doi/full/10.1056/NEJMoa1315226#t=article
Obinutuzumab (Gazyva) Chemotherapy Drug Information http://chemocare.com/chemotherapy/drug-info/obinutuzumab.aspx
Fiorenza, S., Ritchie, D.S., Ramsey, S.D. et al. Value and affordability of CAR T-cell therapy in the United States. Bone Marrow Transplant 55, 1706–1715 (2020). https://doi.org/10.1038/s41409-020-0956-8
Kriegsmann K, Kriegsmann M, Witzens-Harig M. Acalabrutinib, A Second-Generation Bruton’s Tyrosine Kinase Inhibitor. Recent Results Cancer Res. 2018;212:285-294. doi: 10.1007/978-3-319-91439-8_14. PMID: 30069636.